EVP Marion McCourt responded that EYLEA HD's profile, including durability and potential label enhancements, strengthens its competitive position. Tyler Van Buren, TD Cowen: Asked about the timing ...

Listed below are the charts and positions for Eylea HD in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Eylea HD.

For EYLEA HD, label expansions and a prefilled syringe are expected to drive uptake. Libtayo is targeting new approvals in skin and lung cancers. Dupixent is expanding into COPD, chronic urticaria ...

While the initial uptake of Eylea HD was encouraging as Eylea patients ... SNY and REGN are working to expand the drug’s label further. The FDA earlier approved Dupixent for chronic obstructive ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

They are currently working on a higher-dose version of the medicine to compete with Eylea HD. Teva Pharmaceutical Industries shares climbed about 3% Tuesday morning following the release ...

The Business Research Company's Eylea HD Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early ...

The submission is based on positive three-year results from open-label extension studies of the ... million patient-years of experience worldwide. Eylea 8 mg (aflibercept 8 mg; in the United States: ...